secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001104659-23-030189
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma reports FY2022 net loss of $9.4M; advances QRX003 trials for Netherton Syndrome
--------------------------------------------------------------------------------

- FY2022 net loss $9.4M; Q4 net loss $2.0M; cash & marketable securities $12.9M at year-end.
- Dosed first patient in double-blinded placebo-controlled study of QRX003 for Netherton Syndrome.
- Initiated second clinical trial of QRX003 in Netherton patients on off-label systemic therapy (FDA cleared).
- Completed public offering post-quarter with ~$6M net proceeds, extending cash runway into H2 2024.
- Working toward clinical testing in Australia for Scleroderma/Netherton programs in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/0001104659-23-030189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/tm238968d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-030189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer